This Anticancer Fund RFA seeks to increase clinical trial activities in patients diagnosed with Brain Metastases (BM), including Leptomeningeal metastases (LM). We are looking for innovative approaches that can improve survival rate in this specific patient population. The focus is on clinical trials assessing interventions that can increase survival or induce durable responses.

Despite of numerous registered trials and efforts in this patient population, there is still a high need of new and successful treatment options due to the rate of uncompleted and terminated trials. To limit trial execution failure, prioritisation will be given to applicants that have successfully conducted clinical trials in this patient population in the past and have a track record in conducting clinical trials in BM and/or LM.

We welcome applications from all over the world and do not have geographical restrictions.

Deadline for submission of the LOI is Sunday 1 May 2022, 23:59 CET

As ACF seeks proposals in line with its vision and mission, the proposed intervention must be commercially neglected (as defined in detail in the eligibility criteria).

For further details visit: https://www.anticancerfund.org/en/clinical-trials-brain-metastases